New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
06:31 EDTOREXOrexigen receives three month extension of FDA NB32 review
Orexigen announced that the FDA has extended its review of the resubmitted New Drug Application for NB32, the company's investigational medication being evaluated for weight loss. The new Prescription Drug User Fee Act action date has been set for September 11. The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular outcomes for NB32. The NDA resubmission package includes interim safety and CV outcomes data from the ongoing 8,900 patient Light Study. Discussions around the package insert and other post-marketing obligations are ongoing.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
16:17 EDTOREXBaupost reports 17.17% passive stake in Orexigen
Subscribe for More Information
October 6, 2015
06:51 EDTOREXOrexigen price target lowered to $11 from $21 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for Orexigen shares to $11 saying traction for Contrave, while good, is slightly below his expectations. He continues to view Contrave as a "novel asset" with large market potential of $700M in annual revenue, however. Duncan views the company's current market capitalization of $270M as a "market inefficiency" relative to the potential of the Contrave franchise. Duncan reiterates an Overweight rating on Orexigen.
October 1, 2015
08:46 EDTOREXOrexigen announces submission of Contrave NDA in South Korea
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use